Yilu’s practice focuses on intellectual property transactions in the technology and life sciences spaces. She advises public and private technology, biotechnology and pharmaceutical companies, and their investors, in a range of strategic transactions, including licensing and collaboration agreements, supply and distribution arrangements, research-related agreements, mergers and acquisitions, and other commercial agreements and general intellectual property matters. Yilu also counsels clients on data security and privacy issues.
Prior to joining Ropes & Gray, Yilu received the Ann Petluck Poses Memorial Prize for her work as a student attorney in NYU Law’s Technology, Law, and Policy Clinic. She previously worked as a paralegal in the Health Care Fraud unit of the U.S. Attorney’s Office for the District of Massachusetts.
- Advised a biotechnology company in a global agreement worth over $1.5 billion to develop and commercialize treatments for mood and movement disorders.
- Represented Takeda Pharmaceutical Company Limited in renewing collaboration agreements with the Tri-Institutional Therapeutics Discovery Institute, made up of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine (TDI) and with Bridge Medicines, a biotech company launched by Takeda, TDI, and other investors.
- Represented LogicBio Therapeutics, Inc. in its $70 million initial public offering.
- Represented a global investment company in monitoring and enforcement of its global trademark portfolio.
- Advised a global investment firm in developing an organization-wide General Data Protection Regulation (GDPR) compliance program.
- Represented ImmunoGen Inc. in an exclusive collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. to develop and commercialize mirvetuximab soravtansine, a treatment for ovarian cancer, in Greater China.
- Represented Takeda Pharmaceutical Company Limited in a strategic collaboration valued at up to $2 billion with Neurocrine Biosciences, Inc. to develop and commercialize possible psychiatric therapies within Takeda’s early-to-mid-stage portfolio, including an exclusive, worldwide license to Neurocrine for seven psychiatry pipeline programs related to schizophrenia, treatment-resistant depression and anhedonia.
- Yilu Zhang, “The Incompatibility of Bitcoin’s ‘Strong’ Decentralization Ideology and Its Growth as a Scalable Currency,” 11 N.Y.U. J. L. & Liberty 1 (2017)
- Yilu Zhang, “An Analysis of Quill and Federal Remote Sales Tax Legislation,” State Tax Notes (July 4, 2016)
- Presenter, “GDPR for IP (and Other) Lawyers,” Boston Bar Association (April 24, 2019)
- JD, New York University School of Law, 2017
- BA (History), magna cum laude, University of Pennsylvania, 2012
- BS (Economics), magna cum laude, University of Pennsylvania, 2012